Wang, Weiguang - University of Wolverhampton - Faculty of Science & Engineering

个人简介

Weiguang obtained his MB in Hebei United University, China; Msc/MD in Beijing Postgraduate Medical School/PLA 301 Hospital, Beijing; PhD in Manchester Metropolitan University, Manchester, UK. Before joining University of Wolverhampton in 2005, he worked as a research fellow and senior research scientist in Paterson Institute for Cancer Research, Manchester, Institute of Medicine and Therapeutics, Aberdeen and Beatson Institute for Cancer Research, Glasgow. He joined the University of Wolverhampton as a Senior Lecturer in May 2005 and was promoted to Reader and Professor in 2007 and 2014 respectively.

研究领域

Targeting NF-κB pathway to improve cancer chemotherapy outcomes. Using microarray technology, Professor Wang identified NF-κB as a biological factor involved in cancer chemoresistance (Wang et al., Cancer Res 1998, 58:4426-33; 2004, 64:8167-76). Targeting NF-κB, using a clinically available antialcoholism drug, disulfiram (DSF), significantly enhances the cytotoxicity of conventional anticancer drugs to a wide range of cancer types and reverses chemoresistance in drug-resistant cancer cells. The anticancer mechanisms of DSF are investigated in his team. His group is aiming to identify NF-κB-targeting small molecules for anticancer drug development. Manipulation of NF-κB pathway to target cancer stem cells. Cancer contains a very small portion of cancer stem cells (CSCs) which are highly resistant to conventional anticancer drugs and become the source of post-chemotherapeutic cancer recurrence. In the recent years, Weiguang’s team demonstrated that NF-κB pathway is one of the key regulators of CSCs. In collaboration with scientists in China, Spain and USA, they have developed nano-encapsulated long circulating DSF which shows anti-CSC activity in vitro and in vivo.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Effective elimination of adult B-lineage acute lymphoblastic leukemia by Disulfiram/copper complex in vitro and in xenograft immunodeficient mice Manman Deng,Zhiwu Jiang,Yin Li, Yong Zhou, Jie Li, Xiangmeng Wang, Yao Yao, Weiguang Wang*, Peng Li*, Bing Xu*. Oncotarget 2016 in press *Correspondence author Tawari P, Wang Z, Najlah M, Tsang TW, Kannappan V, Liu P, McConville C, He B, Armesilla AL and Wang W. The cytotoxic mechanisms of Disulfiram and copper(II) in cancer cells. Toxic Res. 2015; 4:1439-42 McConville C, Tawari P and Wang W. Hot Melt Extruded and Injection Moulded Disulfiram-loaded PLGA Millirods for the Treatment of Glioblastoma Multiforme via Stereotactic Injection. Int J Pharma. 2015; 494:73 – 82 Li Y, Chen K, Zhou Y, Xiao Y, Deng m, Li J, Jiang Z, Wang X, Ye W, Liang J, Zheng Z, Wei X, Yao Y, Wang W, Li P, Xu B. A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor. Curr Cancer Drug Targets 2015; 15:493 – 503 Zembko I, Ahmed I, Farooq A, Dail J, Tawari P, Wang W, Mcconville C. Development of Disulfiram-Loaded Poly(Lactic-co-Glycolic Acid)Wafers for the Localised Treatment of Glioblastoma Multiforme: A Comparison of Manufacturing Techniques. J Pharma Sci 2015; 104:1076-86 Baffoe CS, Nguyen N, Boyd P, Wang W, Morris M, McConville C. Disulfiram-loaded immediate and extended release vaginal tablets for the localised treatment of cervical cancer. J Pharm Pharmacol 2015; 67:189-98 Boyd P, Major I, Wang W and McConville C. Development of Disulfiram-Loaded Vaginal Rings for the Localised Treatment of Cervical Cancer. Eur J Pharmaceutics Biopharmaceutics 2014; 88:945-53 Baggott R, Alfranca A, Lopez-Maderuelo D, Mohamed T, Escolano A, Oller J, Ornes B, Kurusamy S, Rowther F, Brown J, Oceandy D, Cartwright E, Wang W, Gomez-del Arco P, Martinez-Martinez S, Neyses L, Redondo JM, and Armesilla AL. The Plasma Membrane Calcium ATPase isoform 4 inhibits VEGF-mediated angiogenesis through interaction with calcineurin. Arterios Throm Vascul Biol 2014 In press Liu P, Wang Z, Brown S, Kannappan V, Tawari PE, Jiang W, Irache JM, Tang JZ, Armesilla AL, Darling JL, Tang X and Wang W. Liposome encapsulated Disulfiram inhibits NFkB pathway and targets breast cancer stem cells in vitro and in vivo. Oncotarget 2014; 5:7471-85 Yang L, Ren Y, Yu X, Qian F, Bian BSJ, Wang W, Xiao HL, Xu SL, Yang J, Cui W, Liu Q, Wang Z, Guo W, Xiong G, Yang K, Qian C, Zhang X, Cui YH, Bian XW. ALDH1A1 defines invasive cancer stem-like cells and predicts poor prognosis in patients with esophageal squamous cell carcinoma. Mod Pathol. 2014 May;27(5):775-83